Please login to the form below
AI drug discovery
This page shows the latest AI drug discovery news and features for those working in and with pharma, biotech and healthcare.
Sanofi and AI specialist Aqemia enter $140m drug discovery partnership
targets. Unlike typical AI-based platforms that require experimental data to train on, Aqemia says it "tackles drug discovery projects from their earliest stage" by generating its own data with unique ... The announcement comes less than two months after
Latest news
-
Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
The collaboration will see Boehringer use an IBM-developed AI model to boost its drug discovery efforts. ... The companies noted that, despite “major" technological advances, the discovery and development of therapeutic antibodies against diverse
-
Almirall and Absci announce $650m AI dermatological drug discovery partnership
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology. ... Almirall and Absci have announced a drug discovery partnership aimed at developing and commercialising artificial intelligence (AI)-designed treatments for
-
AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn
Cellectis will also be eligible to receive an investigational new drug option fee and development, regulatory and sales-related milestone payments ranging from $70m up to $220m per each of the ... In September, Alexion partnered with AI-drug discovery
-
Sanofi partners with AI specialist BioMap in deal worth more than $1bn
Sanofi has entered into a strategic collaboration agreement with AI specialist BioMap to accelerate drug discovery for biotherapeutics, with the deal potentially worth over $1bn. ... The partnership will combine BioMap’s AI platform with Sanofi’s
-
ICR and Merck renew strategic alliance for development of new cancer drugs
Throughout the multi-year, multi-target collaboration, both organisations will contribute their expertise in drug discovery to the partnership. ... Most recently, Merck entered into two strategic collaborations to strengthen AI-driven drug discovery
More from news
Approximately 2 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
How AI is finally helping rare diseases gain more than just attention
How AI can break the impasse. In the last decade, we’ve seen a real renaissance in AI and how it can be applied to drug discovery. ... It’s no surprise then that it has also spun-out a separate company, Isomorphic Labs, to apply this process
-
AI and accelerated computing ring in new era for healthcare
How AI can reduce drug discovery timelines. Today, we can produce more biomedical data in about three months than the entire 300-year history of healthcare. ... Application frameworks bridge this gap by providing researchers and clinicians the tools for
-
Switzerland: a life sciences hub
Novartis is investing in artificial intelligence, in alliance with Microsoft, to improve processes, drug design and manufacturing. ... Big data and healthcare. Switzerland is also home to all the major IT companies and both pharma and biotechs are
-
Has AI been the key to tackling the COVID-19 pandemic?
attributes of the drug, they can also uncover whether drugs previously used for other treatments could be an effective cure for this virus. ... UK-based BenevolentAI is just one such company that has used AI and machine learning to aid drug discovery.
-
AI: the smart money is on the smart thinking
Drug discovery. AI has the potential to significantly reduce the costs and time associated with drug discovery, across medical divisions and also specifically in handling the immediate COVID threat. ... achieve. Insilico Medicine was able to do this
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Perlmutter is set to join the board of AI drug discovery biotech Insitro. ... Merck’s R&D chief Roger Perlmutter (pictured above) is set to leave the company after seven years, heading to join the board at AI drug discovery biotech Insitro.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
Dr. Shahar Keinan, Co-founder &CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve precision
-
Advancing Drug Discovery with Structured and Intelligent Data
Michael Wilson and Craig Knox, co-founders of DrugBank, discuss how their comprehensive drug database can be used together with AI and machine learning for drug discovery and repurposing, clinical research,
-
Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
Dr. Shahar Keinan, Co-founder &CEO of POLARIS Quantum Biotech, explores quantum computing and AI for drug discovery, the Quantum Molecular Design process, and how POLARISqb is working to improve precision
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
